LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Why Age-Tech is the new Fin-Tech

1. Fin-tech start-ups have exploded in value to +$250B, annual financing gr...

Read More

New formulations of existing active substances are...

The Opinion of Advocate General Saugmandsgaard Øe in Abraxis Bioscience (Ca...

Read More

Transforming health and social care: industry pers...

At a roundtable event in London in September 2018, CMS assembled a selectio...

Read More

Vital signs in UK life sciences

In 2017, Professor Sir John Bell published the well-received Life Sciences ...

Read More

Rethinking the growth capital challenge in UK life...

Investors, entrepreneurs and deal makers in the UK life sciences industry m...

Read More

Artios Pharma’s £65m Series B to spur development ...

Key findings:

Read More

Evox Therapeutics raises £35.5m Series B to advanc...

Key learnings: UK biotech Evox Therapeutics recently announced its £35.5 mi...

Read More

Key challenges to scaling up early-stage investmen...

Access to venture capital and effective fundraising tactics are key to buil...

Read More

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More

Interview with Avacta Group's Alastair Smith

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Growing opportunities in cannabinoid-based treatme...

In June 2018 it was announced that venture capital firm Casa Verde Capital,...

Read More

Make Brexit a non-issue for pharma

What is the recipe for keeping business momentum in clinical trials despite...

Read More

Add Your Response